Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 29

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 29
---
 as University Professor and Vice Director of the Department of Dermatology. Dr. Reich is an independent medical director and founder of JeruCON Beratungsgesellschaft mbH Hamburg, where he is a self-employed consultant. Since 2016, Dr. Reich also serves as a medical advisor for TFS HealthScience, a contract research organization. Dr. Reich is also a member of the board of directors of Derma2go AG (Zürich, Switzerland), a privately held teledermatology company, Dermagnostix GmbH (Freiburg, Germany), a privately-held diagnostic medical device company and ProDerma Foundation (Hamburg, Germany), a charitable foundation focusing on dermatological research. Dr. Reich was accredited in Dermatology and Venerology in 2000 and in Allergology in 2003. He received his Dr. med. (M.D. equivalent) from the Technical University Munich (Germany) and his Venia legendi (Ph.D. equivalent) in Dermatology and Venerology from the Georg-August-University (Germany).

18

TABLE OF CONTENTS

EXECUTIVE COMPENSATION COMPENSATION DISCUSSION AND ANALYSIS In this Compensation Discussion and Analysis (“CD&A”), we provide an overview of our compensation philosophy and each element of our executive compensation program with regard to the compensation awarded to, earned by, or paid to our named executive officers (the “NEOs”) during our fiscal year ended December 31, 2024. For the fiscal year ended December 31, 2024, our NEOs, which consisted of all of our executive officers during the year, were:

| Name                      |     | Position                          |
| Dr. Jorge Santos da Silva |     | Chief Executive Officer; Director |
| Matthias Bodenstedt       |     | Chief Financial Officer           |
| Dr. Kristian Reich        |     | Chief Scientific Officer          |

Business Highlights In 2024, we successfully progressed with the development of SLK and made the transition to a late-stage biotechnology company. Business highlights included:

| • | Presented positive 24-week data from our Phase 2 ARGO trial of SLK in Psoriatic Arthritis, showing that continued treatment with SLK led to significant improvements across all key outcomes |

| • | Conducted successful end-of-Phase 2 interactions with the U.S. Food and Drug Administration and the E.U. European Medicines Agency to advance SLK into Phase 3 clinical studies in Hidradenitis Sup